Our Clinical Trial Studies
Semnur Pharma’s clinical development program has successfully completed Phase 1, Phase 2, and Phase 3 trials, each of which demonstrated positive outcomes in terms of safety, efficacy, and tolerability for SP-102 (SEMDEXA™). The results of these earlier studies provide a solid foundation for further investigation.
Phase 1
Phase 2
Phase 3
NDA/MAA Filing
Approved
Currently, planning is underway for a Phase 3 open-label study, which will focus on gathering additional data to confirm the findings from previous phases. This open-label trial is designed to offer a more comprehensive evaluation of the SP-102 (SEMDEXA™) treatment in a real-world clinical setting, providing further insights into its long-term effectiveness and safety profile.
